Clinical trials: HEPATITIS C VIRUS CHRONIC INFECTION
Hepatitis C, Chronic
Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis C
Dendritic cells (DC) play a central role in the activation of T-cell responses and have shown to be very immunogenic in preclinical in vivo and in vitro assays.
- Trial name
- NCT02309086
- Testing
- Autologous dendritic cells transduced with Ad encoding NS3
- Volunteers
- 5 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Hepatitis C, Chronic, Hepatitis C
Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)
Enrolled patients will be recruited to two parallel groups during therapy for Hepatitis C. Patients in the first one will receive a patient assistance program, and patients in the second group will not.
- Trial name
- NCT00728494
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908), Patient Assistance Program
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis c
Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c
Chronic hepatitis C is endemic in Egypt with a high prevalence of the resistant genotype 4. Conventional standard of care treatment has modest response with only 50% sustained virologic response.
- Trial name
- NCT01655966
- Testing
- vitamin D +pegylated interferon + ribavirin, pegylated interferon + ribavirin
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Cairo University
Chronic Hepatitis C
HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b
Sustained virological response (SVR) to antiviral therapy in patients with chronic hepatitis C genotype 1 according to subtype (1a vs.1b) has not been extensively investigated.
- Trial name
- genotype (NCT01342003)
- Where
- Italy
- Volunteers
- 388 people
- Sponsor
- Azienda Ospedaliera San Camillo Forlanini
Hepatitis C, Chronic
Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C
The purpose of this study is to examine the rapid virologic response (RVR) at combination therapy (CT) Week 4 between groups receiving a standard combination peginterferon alfa-2b/viramidine dosing regimen versus a cohort that…
- Trial name
- NCT00305383
- Testing
- Viramidine, Peginterferon alfa-2b
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Bausch Health Americas, Inc.
Hepatitis C
Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients
The purpose of this study is to determine whether 24 week treatment with the Daclatasvir (DCV) in combination with Pegylated-interferon alfa 2a (pegIFNα-2a) and Ribavirin (RBV) is safe and demonstrates rate of Sustained Virologic…
- Trial name
- COMMAND-Asia (NCT01797848)
- Testing
- Peginterferon alfa 2a, Ribavirin, Daclatasvir
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1
The purpose of the study is to evaluate the efficacy and safety of Albuferon in combination with ribavirin in interferon (IFN) alfa treatment-naïve subjects with chronic hepatitis C genotype 1.
- Trial name
- NCT00115908
- Testing
- Albuferon, Ribavirin, PEG-IFNalfa2a
- Where
- 87 sites in Australia, Canada and 6 more
- Volunteers
- 458 people
- Sponsor
- Human Genome Sciences Inc.
Chronic Hepatitis C
A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C
This dose-escalating study is to evaluate the efficacy and the safety of different doses of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA) and Ribavirin（RBV） in the…
- Trial name
- NCT01908335
- Testing
- PEG-IFN-SA /RBV low dose, PEG-IFN-SA /RBV middle dose, PEG-IFN-SA /RBV high dose
- Where
- 52 sites in China
- Volunteers
- 212 people
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
HIV Infections, Hepatitis C
Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4
A study concerning viral kinetic with 10 co-infected HIV-HCV patients on treatment with peginterferon alfa-2a + ribavirin o IFN + ribavirin was reported in Conference on Retroviruses and Opportunistic Infections 2002 by Dr.
- Trial name
- NCT00612755
- Testing
- Peginterferon alfa-2a + ribavirin
- Where
- 19 sites in Spain
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Hospital Clinico Universitario San Cecilio
Chronic Hepatitis C, Oxidative Stress
Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C
The purpose of this study is to determine if the safety, metabolism, and antioxidant activity of silymarin and green tea extract are changed when they are given in combination to patients with chronic hepatitis C infection.
- Trial name
- NCT01018615
- Testing
- silymarin, green tea extract (EGCG)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of North Carolina, Chapel Hill
Chronic Hepatitis c
Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model
Background and Aims: The prevalence of hepatitis C virus infection (HCV) infection in Punjab, India is 3.29%, with an estimated burden of around 650,000 viremic chronic HCV (CHC) patients.
- Trial name
- NCT03488485
- Testing
- Direct Acting Antivirals
- Where
- India
- Volunteers
- 50,000 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Hepatitis C
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection
This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) plus ribavirin (RBV) in Japanese participants with chronic genotype 2 hepatitis C virus (HCV) infection.
- Trial name
- NCT01910636
- Testing
- Sofosbuvir, RBV
- Where
- 19 sites in Japan
- Volunteers
- 153 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
This prospective observational study will assess the insulin resistance and its impact on sustained virological response in patients with hepatitis C treated with Pegasys and Copegus.
- Trial name
- NCT01200225
- Where
- France
- Volunteers
- 1,155 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV
The purpose of this study is to evaluate the antiviral efficacy of Boceprevir-based therapy for the treatment of genotype 6 chronic hepatitis C infection.
- Trial name
- HCV-6 (NCT01949168)
- Testing
- Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets), Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection, Rebetol® (ribavirin), 1000/1200mg by mouth daily
- Where
- 4 sites in Australia
- Volunteers
- 30 people
- Sponsor
- St Vincent's Hospital Melbourne
Hepatitis C
Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes
This proposal seeks to use DNA analyses to understand how racial and genetic factors influence interferon (treatment) response in HCV infection in African Americans.
- Trial name
- NCT00324389
- Testing
- Interferon alpha
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic
PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)
This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) and…
- Trial name
- NCT01070550
- Testing
- Peginterferon alfa-2a (Pegasys®)
- Where
- 266 sites in Austria, Brazil and 12 more
- Volunteers
- 4,680 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection
This study seeks to evaluate the efficacy and safety of ABT-493/ABT-530 in participants with Genotype 1 hepatitis C virus infection without cirrhosis
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, HCV
- Trial name
- NCT02604017
- Testing
- ABT-493/ABT-530
- Volunteers
- 703 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis
This Phase II, open-label, parallel-arm study will evaluate the safety, tolerability, pharmacokinetics and antiviral activity of ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and Copegus…
- Trial name
- NCT01749150
- Testing
- danoprevir + ritonavir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Where
- 13 sites in South Korea, Taiwan and 1 more
- Volunteers
- 61 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in treatment-naïve patients with (Genotype 1) hepatitis C.
- Trial name
- NCT00780416
- Testing
- MP-424, Ribavirin, Peginterferon Alfa-2b
- Where
- Japan
- Volunteers
- 189 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C, Chronic
480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)
The purpose of this 12-week study was to assess in subjects with chronic hepatitis C (treatment-naïve, genotype 1) receiving weight-based doses of ribavirin the early virologic response to the 480 ug dose level of Locteron™…
- Trial name
- 480S (NCT00953589)
- Testing
- ribavirin
- Where
- 15 sites in Bulgaria, Israel and 1 more
- Volunteers
- 74 people
- Sponsor
- Biolex Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.